genOway

Equities

ALGEN

FR0004053510

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 09:46:14 2024-04-26 am EDT			5-day change	1st Jan Change
3.97 ^EUR	+0.25%		+1.02%	-13.70%

2023	GenOway: sharp rise, broker initiates buy recommendation	CF
2023	GENOWAY : Euroland initiates buy coverage	CF

GenOway Société anonyme announced that it expects to receive €5 million in funding from NextStage AM

May 05, 2021

genOway Société anonyme (ENXTPA:ALGEN) announced a private placement 1,250,000 common shares at an issue price of €4 per share for gross proceeds of about €5,000,000 on May 6, 2021. The transaction will include participation from institutional investors and company executives.

Latest news about genOway

GenOway: sharp rise, broker initiates buy recommendation	Nov. 22	CF
GENOWAY : Euroland initiates buy coverage	Nov. 22	CF
GenOway: profitability target achieved ahead of schedule	23-09-22	CF
GenOway Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-20	CI
Global markets live: Exxon Mobil, Apple, KKR, Amazon, Tesla...	23-04-11
GenOway Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-19	CI
Sigma-Aldrich and genOway Expand Their CRISPR/CAS9 Strategic Alliance	22-09-08	CI
GenOway Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-28	CI
GenOway Grants the Leading UK Academic Research Funder A Non-Exclusive License for CRISPR/Cas9 Technology	22-01-25	CI
Global markets live: Michelin, Facebook, UBS, Tesla, Volvo...	21-10-26
Genoway Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2021	21-09-27	CI
GenOway Société anonyme announced that it has received €5.6 million in funding from NextStage AM	21-05-26	CI
GenOway Société anonyme announced that it expects to receive €5 million in funding from NextStage AM	21-05-05	CI
Genoway Soci?T? Anonyme Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-30	CI
Genoway S.A. Reports Earnings Results for the Half Year Ended June 30, 2020	20-09-17	CI
GenOway S.A. announced that it has received €1.7 million in funding from Eximium SAS, Dassault Développement and other investors	20-01-27	CI
GenOway and Merck Strengthen CRISPR/Cas9 Strategic Alliance by Extending Partnership to All Animal Cell Models	20-01-07	CI
Merck and genOway Form CRISPR/Cas9 Strategic Alliance to Develop Rodent Models	18-12-10	CI
GenOway S.A. acquired AXENIS S.A.S from Institut Pasteur de Lille.	18-09-24	CI
GenOway Société Anonyme agreed to acquire AXENIS S.A.S from Institut Pasteur de Lille for €0.19 million.	18-09-03	CI

Chart genOway

Duration

Period

More charts

Company Profile

Sector

Biotechnology & Medical Research

Calendar

2024-06-27 - Shareholders Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GENOWAY	-13.70%	38.19M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research